Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Benkert, Thomas F ^a   Dietz, Lena ^a   Hartmann, Elena M ^a   Leich, Ellen ^a   Rosenwald, Andreas ^a   Serfling, Edgar ^a   Buttmann, Mathias ^a   Berberich Siebelt, Friederike ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; AZATHIOPRINE; BETA INTERFERON; GAMMA INTERFERON; GLATIRAMER; INTEGRIN; INTERLEUKIN 17; INTERLEUKIN 2; LYMPHOKINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOXANTRONE; MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DOWN REGULATION; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; EFFECTOR CELL; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INTERNALIZATION; INTRACELLULAR SIGNALING; MALE; MULTIPLE SCLEROSIS; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REBOUND; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HUMANS; INTEGRIN ALPHA4; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-2; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE SCLEROSIS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84871457288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052208     Document Type: Article

References (54)

1. Compston A, Coles A, (2002) Multiple sclerosis. Lancet 359: 1221-1231.
2. Hohlfeld R, Wekerle H, (2001) Immunological update on multiple sclerosis. Curr Opin Neurol 14: 299-304.
3. Korn T, (2008) Pathophysiology of multiple sclerosis. J Neurol 255Suppl 6: 2-6.
4. Benvenuto R, Paroli M, Buttinelli C, Franco A, Barnaba V, et al. (1992) Tumor necrosis factor-alpha and interferon-gamma synthesis by cerebrospinal fluid-derived T cell clones in multiple sclerosis. Ann N Y Acad Sci 650: 341-346.
5. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, et al. (1993) T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes. Autoimmunity 15: 137-143.
6. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
7. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, et al. (2009) Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 66: 390-402.
8. Hynes RO, (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687.
9. Kinashi T, (2005) Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol 5: 546-559.
10. Schwartz MA, Ginsberg MH, (2002) Networks and crosstalk: integrin signalling spreads. Nat Cell Biol 4: E65-68.
11. Dore-Duffy P, Washington R, Dragovic L, (1993) Expression of endothelial cell activation antigens in microvessels from patients with multiple sclerosis. Adv Exp Med Biol 331: 243-248.
12. Washington R, Burton J, Todd RF 3rd, Newman W, Dragovic L, et al (1994) Expression of immunologically relevant endothelial cell activation antigens on isolated central nervous system microvessels from patients with multiple sclerosis. Ann Neurol 35: 89-97.
13. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr, (1993) Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177: 57-68.
14. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356: 63-66.
15. Steinman L, (2005) Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 4: 510-518.
16. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
17. Buttmann M, (2010) Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother 10: 791-809.
18. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al. (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366: 1870-1880.
19. Kleinschmidt-DeMasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T, (2012) Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 71: 604-617.
20. Miravalle A, Jensen R, Kinkel RP, (2011) Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 68: 186-191.
21. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A, (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77: 1061-1067.
22. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, et al. (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9: 438-446.
23. O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, et al. (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76: 1858-1865.
24. Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, et al. (2011) Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 308: 98-102.
25. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH, (2008) Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 70: 1150-1151.
26. West TW, Cree BA, (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68: 395-399.
27. Rigau V, Mania A, Befort P, Carlander B, Jonquet O, et al. (2012) Lethal Multiple Sclerosis Relapse after Natalizumab Withdrawal. Neurology.
28. Kivisakk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, et al. (2009) Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72: 1922-1930.
29. Frisullo G, Iorio R, Plantone D, Marti A, Nociti V, et al. (2011) CD4+T-bet+, CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment. Mult Scler 17: 556-566.
30. Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, et al. (2011) Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol 31: 623-631.
31. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
32. Beck O, Topp MS, Koehl U, Roilides E, Simitsopoulou M, et al. (2006) Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 107: 2562-2569.
33. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, et al. (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19: 345-354.
34. Gomez IG, Tang J, Wilson CL, Yan W, Heinecke JW, et al. (2012) Metalloproteinase-mediated Shedding of Integrin beta2 promotes macrophage efflux from inflammatory sites. J Biol Chem 287: 4581-4589.
35. Redondo-Munoz J, Ugarte-Berzal E, Garcia-Marco JA, del Cerro MH, Van den Steen PE, et al. (2008) Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112: 169-178.
36. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, et al. (2010) Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 227: 190-194.
37. Niino M, Bodner C, Simard ML, Alatab S, Gano D, et al. (2006) Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 59: 748-754.
38. Fleming JC, Bao F, Cepinskas G, Weaver LC, (2010) Anti-alpha4beta1 integrin antibody induces receptor internalization and does not impair the function of circulating neutrophilic leukocytes. Inflamm Res 59: 647-657.
39. Mittelbrunn M, Molina A, Escribese MM, Yanez-Mo M, Escudero E, et al. (2004) VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A 101: 11058-11063.
40. Nguyen K, Sylvain NR, Bunnell SC, (2008) T cell costimulation via the integrin VLA-4 inhibits the actin-dependent centralization of signaling microclusters containing the adaptor SLP-76. Immunity 28: 810-821.
41. Garron ML, Arthos J, Guichou JF, McNally J, Cicala C, et al. (2008) Structural basis for the interaction between focal adhesion kinase and CD4. J Mol Biol 375: 1320-1328.
42. Westhoff MA, Serrels B, Fincham VJ, Frame MC, Carragher NO, (2004) SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol 24: 8113-8133.
43. Kim TK, Billard MJ, Wieder ED, McIntyre BW, Komanduri KV, (2010) Co-engagement of alpha(4)beta(1) integrin (VLA-4) and CD4 or CD8 is necessary to induce maximal Erk1/2 phosphorylation and cytokine production in human T cells. Hum Immunol 71: 23-28.
44. Muller MR, Rao A, (2010) NFAT, immunity and cancer: a transcription factor comes of age. Nat Rev Immunol 10: 645-656.
45. Sakaguchi S, Yamaguchi T, Nomura T, Ono M, (2008) Regulatory T cells and immune tolerance. Cell 133: 775-787.
46. Frisullo G, Nociti V, Iorio R, Patanella AK, Caggiula M, et al. (2009) Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology 127: 418-428.
47. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T, (2008) Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111: 3439-3441.
48. Neumann F, Zohren F, Haas R, (2009) The role of natalizumab in hematopoietic stem cell mobilization. Expert Opin Biol Ther 9: 1099-1106.
49. Saure C, Warnke C, Zohren F, Schroeder T, Bruns I, et al. (2011) Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol 68: 1428-1431.
50. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, et al. (2009) The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 16: 528-536.
51. Khademi M, Stol D, Olsson T, Wallstrom E, (2008) Induction of systemic TNFalpha in natalizumab-treated multiple sclerosis. Eur J Neurol 15: 309-312.
52. Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L, (2008) Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 194: 153-164.
53. Oreja-Guevara C, Ramos-Cejudo J, Stark Aroeira L, Chamorro B, Diez-Tejedor E, (2012) TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol 12: 95.
54. McCombe JA, Auer RN, Maingat FG, Houston S, Gill MJ, et al. (2009) Neurologic immune reconstitution inflammatory syndrome in HIV/AIDS: outcome and epidemiology. Neurology 72: 835-841.